Skip to main content

Table 1 Clinical–pathological characteristics of patients and tumours (n = 15)

From: Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes

Age [y] 62.1 ± 4.1 (53–68)*
Weight [kg] 88.8 ± 11.4 (65–109)*
Height [cm] 177.4 ± 6.1 (170–191)*
PSA [ng/mL] 9.4 ± 6.3 (3.5–25.5)*
Injected [18F]DCFPyL activity [MBq] 312.4 ± 15.9 (280.8–348.2)*
Histology—n(%)
Adenocarcinoma 15 (100)
pT Stage—n(%)
 T2c 7 (46.7)
 T3a 7 (46.7)
 T3b 1 (6.7)
pN Stage—n(%)
 N0 15 (100)
 N1 0 (0)
 NX 0 (0)
pM Stage—n(%)
 M0 15 (100)
 M1 0 (0)
 MX 0 (0)
Gleason score of DIL—n(%)
 6 (3 + 3) 1 (6.7)
 7 (3 + 4) 6 (40.0)
 7 (4 + 3) 5 (33.3)
9 (5 + 4) 3 (20.0)
  1. Data are the number of patients with the percentage in parentheses unless otherwise indicated
  2. DCFPyL 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, PSA prostate-specific antigen, pT primary tumour, pN lymph node, pM distant metastasis, DIL dominant intraprostatic lesion
  3. *Data are means ± standard deviation, with the range in parentheses